Clinical trial · Interventional
The Randomized Controlled Clinical Trial of Kushen Injection
The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The randomized controlled multicenter clinical study of compound Kushen Injection to reduce the radiotherapy related adverse reactions in lung cancer is a phase Ⅳ clinical trials，The main purpose is to evaluate the effect of compound Kushen Injection in preventing and reducing the radiotherapy related adverse reactions. The participants of the clinical trials are patients with lung cancer who need thoracic radiotherapy. In clinical trials, one group of participants is given compound Kushen Injection with chemoradiotherapy, while another group is only given chemoradiotherapy. The period of trials is 18 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Compound Kushen Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- KS injection arm
- description
- Radiation and chemotherapy and compound Kushen Injection
- interventionNames
- Drug: Compound Kushen Injection
- type
- NO_INTERVENTION
- label
- Control arm
- description
- Radiation and chemotherapy
Primary outcomes (1)
- measure
- The rates of incidence and the degree of adverse reactions caused by redioterapy
- timeFrame
- 6 months
- description
- radio-pulmonary lesion,radiation esophagitis,Radiation Induced Heart Disease
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Before the start of the study, All patients have been fully understood the reseach and the must sign the informed consent * To be aged from 18 to 75 years old, both gender * The lung cancer diagnosis must be proved by pathology * According to RECIST (version 1.1), At least 1 objectively measurable Tumor lesion (iconography: CT, MRI), the assessable lesion can be measured accurately, maximum diameter more than at least 10mm (Malignant lymph nodes on CT scans short diameter less than at least 15 mm) * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 * Lung function FEV1 more than at least 1Land more than 50% A normal value * The function of each organ is basically normal :ANC more than 1.5\*10\^9/L, Platelet count more than 100\*10\^9/L, Hb more than 9.0g/dl, BIL at normal level or less than 1.5\*ULN, AST (SGOT), ALT (SGPT) less than 2.5\*ULN(less than 5\*ULN, if with liver metastases), SCr less than 1.5\*ULN * The expected survival tme must more than 6 months. Exclusion Criteria: * Lung or mediastinal have received radiotherapy before or ever treated with Compound Kushen Injection within 2weeks * Pregnancy or lactation women * Patients with severe, uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy - Participating or within the last 30 days participated in other clinical trials * Hypersensitiveness to any kind of trial regime * Had a history of serious Psychological or Psychiatric disorders, Drug addiction or Alcohol dependence * Estimating the compliance of patients to participate in this clinical trial is insufficient.
References
Publications (0)
Data not yet available